Siemens Group Forms the World's First Full Service Diagnostics

SIEMENSSiemens has been given the green light to acquire the diagnostics division of Bayer Healthcare without restrictions. The approval was granted yesterday by the European Commission, following the earlier approval by U.S. antitrust authorities at the beginning of October. This follows the acquisition of the U.S. firm Diagnostic Products Corporation (DPC), which was completed at the end of July. Upon completion of the Bayer acquisition, which is expected by early 2007, both companies will be merged and will operate as "Siemens Medical Solutions Diagnostics," an U.S.-based subsidiary and part of Siemens Medical Solutions.

"This has paved the way for Siemens to create the world's first full service diagnostics company," explained Prof. Dr. Erich R. Reinhardt, member of the Managing Board of Siemens AG and president and CEO of Siemens Medical Solutions (Med), following the Commission's decision. The successful entry into the in-vitro diagnostics market will allow the company to combine the entire imaging diagnostics, laboratory diagnostics and clinical information technology value chain under one roof and offer its customers customized solutions. "This will further improve the quality and efficiency of healthcare," commented Reinhardt.

The purchase price for Bayer Diagnostics is roughly EUR 4.2 billion; in fiscal 2005 the Group generated sales of EUR 1.4 billion and a double-digit profit margin related to earnings before interest, tax, depreciation and amortization (EBITDA). The acquisitions of Bayer Diagnostics and DPC (the latter completed in July for a purchase price of US$1.86 billion) will make Siemens Medical Solutions No. 2 worldwide in immunodiagnostics. Bayer Diagnostics is also a world market leader in clinical chemistry with a leading position in near-patient testing, laboratory automation and hematology (blood cell diagnostics). In addition, the acquisition of Bayer Diagnostics will enable the Siemens Group to tap the rapidly growing market for molecular diagnostics based on gene analysis (nucleid acid testing).

"Molecular medicine has huge potential to detect diseases such as cancer at a much earlier stage than what is possible today," said Reinhardt. "Molecular medicine is already helping physicians choose suitable medications for a particular patient, predict the effects of those medications and personalize patients' treatments. The long-term vision is to identify and treat the molecular causes of diseases long before the patient ever experiences any symptoms, and Siemens is at the forefront of developing these molecular medicine solutions that will transform the future of healthcare."

Sales of Bayer Diagnostics rose in 2005 by 8.4 percent to EUR 1.4 billion. The division offers an extensive portfolio of in-vitro diagnostic products for evaluating and monitoring the therapy of numerous diseases, including cardiovascular disorders, kidney diseases, infections, cancer and diabetes. The business units are Laboratory Testing, including the ADVIA Centaur(R), Centaur(R) CP and Centaur(R) XP, ADVIA(R) Clinical Chemistry, ADVIA(R) LabCell(R) and WorkCell(R) Automation, ADVIA(R) Hematology and Clinitek(R) Atlas systems; Near Patient Testing with its Rapidpoint(R), Rapidlab(R), RapidComm(TM) and Clinitek(R) brands; and Molecular Testing with its Trugene(R) and Versant(R) lines of tests and systems.

About Siemens Medical Solutions
Siemens Medical Solutions (Med) (NYSE:SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. From imaging systems for diagnosis, to therapy equipment for treatment, to patient monitors to hearing instruments and beyond, Siemens innovations contribute to the health and well-being of people across the globe, while improving operational efficiencies and optimizing workflow in hospitals, clinics, home health agencies and doctors' offices. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and Group profit of 976 million EUR for fiscal 2005 (September 30).
http://www.medical.siemens.com/

Most Popular Now

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...

Helping Cancer Patients Avoid Excessive …

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of...

The Programme for the Union's Action in …

On 24 March 2021, Regulation (EU) 2021/522 of the European Parliament and of the Council1 was adopted as part of the Multiannual Financial Framework for the 2021-2027 period. That Regulation...

CliniSys Acquires HORIZON Lab Systems an…

CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world’s...